Uncategorized-EN

A Study of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (LIGHTBEAM-U01, Substudy 01D) Agent: Ifinatamab deruxtecan (I-DXd; MK-2400) Phase Ib/II Status Recruiting Sponsor Merck Sharp & Dohme LLC   For further information please also consult https://clinicaltrials.gov/study/NCT07630974. LIGHTBEAM-U01 Substudy 01D is a phase 1b/2 study of ifinatamab deruxtecan (I-DXd) in children and…

Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (e.g. Ewing Sarcoma) (LIGHTBEAM-U01, Substudy 01A) Agent: Zilovertamab vedotin Phase I/II Status Recruiting Sponsor Merck Sharp & Dohme LLC   For further information please also consult https://clinicaltrials.gov/study/NCT06395103. LIGHTBEAM-U01 Substudy 01A is a Phase 1/2 study looking at the safety and potential…

A Study of Patritumab Deruxtecan in Children With Relapsed or Refractory Solid Tumors (LIGHTBEAM-U01) Agent: Patritumab deruxtecan (HER3-DXd; MK-1022) Phase I/II Status Recruiting Sponsor Merck Sharp & Dohme LLC   For further information please also consult https://clinicaltrials.gov/study/NCT06941272. LIGHTBEAM-U01 is a phase 1/2 study of patritumab deruxtecan (HER3-DXd) in children and adolescents with rhabdomyosarcoma or hepatoblastoma…

SARATOGA: A Study of Lifileucel in Advanced Soft Tissue Sarcoma Agent: Lifileucel (LN-145) Phase II Status Recruiting Sponsor Iovance Biotherapeutics, Inc.   For further information please also consult https://clinicaltrials.gov/study/NCT07741877. SARATOGA is a Phase 2 study investigating lifileucel (LN-145), a treatment using immune cells collected from a patient’s own tumor, in previously treated advanced soft tissue…

UK: The Harry Kazmi Foundation Back to members The Harry Kazmi Foundation The Harry Kazmi Foundation is a UK-registered charity dedicated to advancing awareness, research and improved outcomes for alveolar rhabdomyosarcoma, a rare and aggressive cancer affecting children, adolescents and young adults. The Foundation works to strengthen understanding of alveolar rhabdomyosarcoma, support research and promote…

A Study Evaluating the Efficacy and Safety of Risvutatug Rezetecan in Advanced Sarcomas (EMBOLD Sarcoma-202) Agent: Risvutatug rezetecan (Ris-Rez); G-CSF in one study group Phase Ib/II Status Recruiting Sponsor GlaxoSmithKline (GSK)   For further information please also consult https://clinicaltrials.gov/study/NCT07602777. EMBOLD Sarcoma-202 is a Phase 1b/2 study of risvutatug rezetecan (Ris-Rez) in adolescents and adults with…

  USA: DSRCT Initiative Back to members Mission of the DSRCT Initiative: To unite everyone impacted by Desmoplastic Small Round Cell Tumor (DSRCT) through community, awareness, accessible disease resources, and direct family support, pursuing a world where no one faces this disease alone or without hope. What we’ve accomplished so far in 2026: The dsrct-initiative.org…

  Uganda: Action Against Cancer  (AACA) Back to members Organisation’s profile  Action Against Cancer (AACA) is a patient-centred cancer advocacy organisation in Uganda dedicated to improving the lives of people affected by cancer. Our mission is to promote cancer awareness, early detection, access to quality care, patient empowerment, and support throughout the cancer journey. Our activities…